Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report released on Sunday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. TD Cowen reiterated a “hold” rating on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. JMP Securities reaffirmed a “market perform” rating on shares of Marinus Pharmaceuticals in a research report on Thursday, October 24th. LADENBURG THALM/SH SH cut Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 14th. Truist Financial lowered Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. Finally, Oppenheimer raised shares of Marinus Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price target for the company in a research report on Monday, September 23rd. Nine investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Marinus Pharmaceuticals presently has an average rating of “Hold” and an average target price of $6.07.

Marinus Pharmaceuticals Trading Down 3.8 %

Shares of MRNS opened at $0.35 on Friday. The firm has a market cap of $19.03 million, a PE ratio of -0.13 and a beta of 1.26. Marinus Pharmaceuticals has a 12 month low of $0.26 and a 12 month high of $11.26. The stock has a fifty day moving average price of $1.33 and a 200-day moving average price of $1.35.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01). The business had revenue of $8.06 million during the quarter, compared to analysts’ expectations of $9.05 million. Marinus Pharmaceuticals had a negative net margin of 493.14% and a negative return on equity of 7,831.35%. During the same quarter last year, the business posted ($0.61) earnings per share. As a group, research analysts forecast that Marinus Pharmaceuticals will post -1.92 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Point72 DIFC Ltd acquired a new stake in shares of Marinus Pharmaceuticals during the 2nd quarter valued at about $28,000. SG Americas Securities LLC acquired a new stake in Marinus Pharmaceuticals in the second quarter valued at approximately $34,000. AQR Capital Management LLC increased its position in shares of Marinus Pharmaceuticals by 70.3% in the second quarter. AQR Capital Management LLC now owns 31,333 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 12,934 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth approximately $64,000. Finally, Values First Advisors Inc. lifted its position in shares of Marinus Pharmaceuticals by 501.8% during the 2nd quarter. Values First Advisors Inc. now owns 62,671 shares of the biopharmaceutical company’s stock valued at $73,000 after buying an additional 52,257 shares in the last quarter. Hedge funds and other institutional investors own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.